GS-441524
A nucleoside analog antiviral drug
| GS-441524 | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
GS-441524 is a nucleoside analog antiviral drug that has been studied for its potential use in treating viral infections, particularly those caused by coronaviruses. It is a prodrug of remdesivir, which is an antiviral medication used to treat COVID-19.
Chemical structure and properties
GS-441524 is a nucleoside analog, meaning it mimics the structure of natural nucleosides, which are the building blocks of nucleic acids like RNA and DNA. The chemical structure of GS-441524 allows it to interfere with the replication of viral RNA, thereby inhibiting the proliferation of the virus within the host organism.
Mechanism of action
GS-441524 works by incorporating itself into the viral RNA chain during replication. This incorporation leads to premature termination of the RNA chain, effectively halting the replication process of the virus. This mechanism is similar to that of other nucleoside analogs, which are commonly used in antiviral therapies.
Clinical applications
While GS-441524 itself is not approved for human use, its prodrug, remdesivir, has been authorized for emergency use in the treatment of COVID-19. GS-441524 has been studied in various animal models and has shown promise in treating infections caused by feline coronavirus, which can lead to feline infectious peritonitis (FIP), a fatal disease in cats.
Research and development
Research into GS-441524 has primarily focused on its efficacy and safety in treating viral infections. Studies have demonstrated its potential in inhibiting the replication of various coronaviruses, including those responsible for SARS and MERS. Ongoing research aims to further understand its pharmacokinetics and potential applications in human medicine.
Related pages
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
